Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| TBTC Study 22 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| US Department of Veterans Affairs | FED |
Primary Objective: To compare, at the completion of the follow-up phase, the clinical and bacteriologic relapse rates associated with the two study regimens.
Secondary Objectives:
To compare the clinical and bacteriologic failure rates of the two study regimens at the completion of the study phase therapy.
To compare the clinical and bacteriologic response rates for the two study regimens among patients who began study phase therapy with signs and symptoms of tuberculosis or cultures positive for M. tuberculosis.
To compare the toxicity associated with the two study regimens by comparing discontinuation rates due to adverse events and occurrence rates of signs and symptoms associated with adverse events during study phase therapy.
To compare mortality rates of the two study regimens. To compare the rates of completion of therapy within 22 weeks for the two study regimens.
To compare the rate of development of drug-resistant tuberculosis in the two study regimens among study patients classified as treatment failures or relapses.
To compare all of the above performance characteristics for the two study regimens in a small subset of HIV seropositive patients.
To compare attitudes and beliefs about participation in this study between patients who complete study therapy and those who fail to complete study therapy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rifapentine | Drug | |||
| Isoniazid | Drug |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Central Arkansas Veterans Health System | Little Rock | Arkansas | 72205 | United States | ||
| LA County/USC Medical Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 12531776 | Background | Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N, Hodge T; Tuberculosis Trials Consortium. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med. 2003 May 15;167(10):1341-7. doi: 10.1164/rccm.200208-951OC. Epub 2003 Jan 16. | |
| 12241657 |
| Label | URL |
|---|---|
| Click here for more information about the Tuberculosis Trials Consortium (TBTC) | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Los Angeles |
| California |
| 90033 |
| United States |
| University of California, San Francisco | San Francisco | California | 94110 | United States |
| Denver Department of Public Health and Hospitals | Denver | Colorado | 80204 | United States |
| Washington, D.C. VAMC | Washington D.C. | District of Columbia | 20422 | United States |
| Chicago VA Medical Center (Lakeside) | Chicago | Illinois | 60611 | United States |
| Hines VA Medical Center | Hines | Illinois | 60141 | United States |
| Johns Hopkins University School of Medicine | Baltimore | Maryland | 21287-0003 | United States |
| Boston Medical Center | Boston | Massachusetts | 02118 | United States |
| New Jersey Medical School | Newark | New Jersey | 07107-3001 | United States |
| New York University School of Medicine | New York | New York | 10016 | United States |
| Columbia University/Presbyterian Medical Center | New York | New York | 10032 | United States |
| Harlem Hospital Center | New York | New York | 10037 | United States |
| Carolinas Medical Center | Charlotte | North Carolina | 28203 | United States |
| Duke University Medical Center | Durham | North Carolina | 34222 | United States |
| Nashville VA Medical Center | Nashville | Tennessee | 37212-2637 | United States |
| University of North Texas Health Science Center | Fort Worth | Texas | 76107-2699 | United States |
| Thomas Street Clinic | Houston | Texas | 77009 | United States |
| Audi L. Murphy VA Hospital | San Antonio | Texas | 78284 | United States |
| Seattle King County Health Department | Seattle | Washington | 98104 | United States |
| University of British Columbia | Vancouver | British Columbia | Canada V5Z 4R4 | Canada |
| University of Manitoba | Winnipeg | Manitoba | CANADA R3A 1R8 | Canada |
| Montreal Chest Institute McGill University | Montreal | Quebec | H2X 2P4Pq Canada | Canada |
| Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, Gordin F, Horsburgh CR, Horton J, Khan A, Lahart C, Metchock B, Pachucki C, Stanton L, Vernon A, Villarino ME, Wang YC, Weiner M, Weis S; Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002 Aug 17;360(9332):528-34. doi: 10.1016/s0140-6736(02)09742-8. |
| 10359410 | Background | Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999 May 29;353(9167):1843-7. doi: 10.1016/s0140-6736(98)11467-8. |
| 20610636 | Derived | Yamshchikov AV, Kurbatova EV, Kumari M, Blumberg HM, Ziegler TR, Ray SM, Tangpricha V. Vitamin D status and antimicrobial peptide cathelicidin (LL-37) concentrations in patients with active pulmonary tuberculosis. Am J Clin Nutr. 2010 Sep;92(3):603-11. doi: 10.3945/ajcn.2010.29411. Epub 2010 Jul 7. |
| ID | Term |
|---|---|
| D014397 | Tuberculosis, Pulmonary |
| ID | Term |
|---|---|
| D014376 | Tuberculosis |
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D012141 | Respiratory Tract Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C018421 | rifapentine |
| D007538 | Isoniazid |
| ID | Term |
|---|---|
| D006834 | Hydrazines |
| D009930 | Organic Chemicals |
| D007539 | Isonicotinic Acids |
| D000147 | Acids, Heterocyclic |
| D006571 | Heterocyclic Compounds |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
Not provided
Not provided